Literature DB >> 2402015

Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.

G Bonadonna1, U Veronesi, C Brambilla, L Ferrari, A Luini, M Greco, C Bartoli, G Coopmans de Yoldi, R Zucali, F Rilke.   

Abstract

In 165 women with breast cancer who were candidates for mastectomy because the largest diameter of the tumor was 3 cm or more, we administered primary chemotherapy in the attempt to substitute conservative for mutilating surgery. We then systematically quantitated tumor reduction by clinical, radiologic, and histopathologic evaluations. Five consecutive groups of 33 patients received cyclophosphamide, methotrexate, and fluorouracil (CMF); fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC); or fluorouracil, epirubicin, and cyclophosphamide (FEC). The regimens for the five groups were as follows: group 1, three cycles of CMF; group 2, four cycles of CMF; group 3, three cycles of FAC; group 4, four cycles of FAC; and group 5, three cycles of FEC. In response to primary chemotherapy, 157 of the 161 assessable patients showed measurable tumor shrinkage; progressive disease was documented in four. Tumor shrinkage to less than 3 cm was documented in 127 (81%) of the 157 women subjected to surgery, thus allowing a breast-saving procedure, rather than modified radical mastectomy, in these 127 women. Histopathologic complete remission was documented in seven patients. Tumor response was unrelated to age, menopausal status, DNA content (ploidy), [3H]thymidine-labeling index, drug combination used, or number of treatment cycles in excess of three. The degree of response was inversely proportional to the initial tumor size, and the frequency of response was greater in receptor-negative tumors. Severe vomiting and hair loss were less frequent with CMF than with anthracycline-containing regimens, and the frequency of severe leukopenia and thrombocytopenia was minimal. Our results challenge the classical indication for primary mastectomy by showing that use of full-dose primary chemotherapy, sequentially combined with conservative surgery and radiation, can offer an effective and safe alternative to women concerned about the preservation of body integrity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2402015     DOI: 10.1093/jnci/82.19.1539

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  74 in total

Review 1.  Management of early breast cancer.

Authors:  R D Rubens
Journal:  BMJ       Date:  1992-05-23

2.  Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer.

Authors:  Mónica Fernández-Sánchez; Armando Gamboa-Dominguez; Norma Uribe; Ana Cristina García-Ulloa; Diana Flores-Estrada; Myrna Candelaria; Oscar Arrieta
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer.

Authors:  Kaptan Gülben; Uğur Berberoğlu; Aziz Cengiz; Hüseyin Altınyollar
Journal:  World J Surg       Date:  2007-09       Impact factor: 3.352

4.  Evaluation of surgical outcomes following oncoplastic breast surgery in early breast cancer and comparison with conventional breast conservation surgery.

Authors:  Ashutosh Chauhan; Mala Mathur Sharma
Journal:  Med J Armed Forces India       Date:  2015-12-13

5.  Treating breast cancer before surgery.

Authors:  R Epstein
Journal:  BMJ       Date:  1996-11-30

Review 6.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 7.  Radiation therapy for early breast cancer.

Authors:  Georgios Koukourakis
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

8.  Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry.

Authors:  I N Fernando; T J Powles; M Dowsett; S Ashley; L McRobert; J Titley; M G Ormerod; N Sacks; M C Nicolson; A Nash
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 9.  Patient selection criteria for conservation surgery versus mastectomy: Memorial Hospital breast service experience.

Authors:  M P Moore; D W Kinne
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

10.  Prognostic factors for local recurrence in breast conservation therapy: residual cancers after lumpectomy.

Authors:  T Fukutomi; H Yamamoto; T Nanasawa; M Itabashi; T Hirota
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.